BIOGY (BioGaia AB) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOGY BioGaia AB BIOGY
99 GF Score
Price $12.45
GF Value $11.90
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is BioGaia AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioGaia AB  (OTCPK:BIOGY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioGaia AB Cyclically Adjusted PS Ratio Related Terms


BioGaia AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Cyclically Adjusted PS Ratio Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.39 8.70 9.19 9.08 9.39

BioGaia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 9.57 9.15 9.02 8.65

BIOGY vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Cyclically Adjusted PS Ratio falls into.


BIOGY
99GF Score
BioGaia AB BIOGY
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioGaia AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, BioGaia AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.465/134.6100*134.6100
=0.465

Current CPI (Jun. 2026) = 134.6100.

BioGaia AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.170 101.138 0.226
201612 0.176 102.022 0.232
201703 0.183 102.022 0.241
201706 0.208 102.752 0.272
201709 0.209 103.279 0.272
201712 0.236 103.793 0.306
201803 0.223 103.962 0.289
201806 0.267 104.875 0.343
201809 0.225 105.679 0.287
201812 0.267 105.912 0.339
201903 0.215 105.886 0.273
201906 0.272 106.742 0.343
201909 0.201 107.214 0.252
201912 0.249 107.766 0.311
202003 0.218 106.563 0.275
202006 0.291 107.498 0.364
202009 0.172 107.635 0.215
202012 0.229 108.296 0.285
202103 0.238 108.360 0.296
202106 0.239 108.928 0.295
202109 0.199 110.338 0.243
202112 0.230 112.486 0.275
202203 0.301 114.825 0.353
202206 0.290 118.384 0.330
202209 0.242 122.296 0.266
202212 0.253 126.365 0.270
202303 0.347 127.042 0.368
202306 0.296 129.407 0.308
202309 0.291 130.224 0.301
202312 0.276 131.912 0.282
202403 0.352 132.205 0.358
202406 0.356 132.716 0.361
202409 0.288 132.304 0.293
202412 0.335 132.987 0.339
202503 0.339 132.825 0.344
202506 0.414 133.699 0.417
202509 0.339 133.480 0.342
202512 0.463 133.380 0.467
202603 0.403 133.550 0.406
202606 0.465 134.610 0.465

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioGaia AB (BIOGY) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be overvalued. The current stock price of $12.45 is trading 4.6% above its estimated GF Value™ of $11.90. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BIOGY:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $11.90 vs. price of $12.45 (4.6% above fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the BIOGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
99GF Score

Get the complete analysis for BIOGY

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.45
Price
$11.90
GF Value